Your browser doesn't support javascript.
loading
Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026).
Bauermeister, José A; Tingler, Ryan C; Dominguez, Clara; Dunne, Eileen F; Hoesley, Craig; Ho, Ken; Johnson, Sherri; Lucas, Jonathan; Macagna, Nicole; Brown, Elizabeth; Gundacker, Holly; Peda, Melissa; Jacobson, Cindy E; Kramzer, Lindsay; Singh, Devika; Dezzutti, Charlene S; Ayudhya, Ratiya Pamela Kunjara Na; Marzinke, Mark A; Piper, Jeanna; Devlin, Bríd; Nuttall, Jeremy; McGowan, Ian; Hendrix, Craig W; Cranston, Ross D.
Affiliation
  • Bauermeister JA; University of Pennsylvania, 418 Curie Blvd, Room 222L, Philadelphia, PA, 19104, USA. bjose@upenn.edu.
  • Tingler RC; University of Pennsylvania, 418 Curie Blvd, Room 222L, Philadelphia, PA, 19104, USA.
  • Dominguez C; Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Dunne EF; ivision of HIV/AIDS Prevention, D, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  • Hoesley C; Thailand Ministry of Public Health-US CDC Collaboration, Bangkok, Thailand.
  • Ho K; University of Alabama at Birmingham, Birmingham, AL, USA.
  • Johnson S; University of Pittsburgh, Pittsburgh, PA, USA.
  • Lucas J; , FHI 360, Durham, NC, USA.
  • Macagna N; , FHI 360, Durham, NC, USA.
  • Brown E; , FHI 360, Durham, NC, USA.
  • Gundacker H; Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Peda M; Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Jacobson CE; Statistical Center for HIV/AIDS Research & Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Kramzer L; Microbicide Trials Network, Pittsburgh, PA, USA.
  • Singh D; Microbicide Trials Network, Pittsburgh, PA, USA.
  • Dezzutti CS; Microbicide Trials Network, Pittsburgh, PA, USA.
  • Ayudhya RPKN; Microbicide Trials Network, Pittsburgh, PA, USA.
  • Marzinke MA; University of Pittsburgh, Pittsburgh, PA, USA.
  • Piper J; Microbicide Trials Network, Pittsburgh, PA, USA.
  • Devlin B; Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Nuttall J; Division of AIDS/NIAID/NIH, Bethesda, MD, USA.
  • McGowan I; International Partnership for Microbicides, Silver Spring, MD, USA.
  • Hendrix CW; International Partnership for Microbicides, Silver Spring, MD, USA.
  • Cranston RD; University of Pittsburgh, Pittsburgh, PA, USA.
AIDS Behav ; 26(5): 1333-1346, 2022 May.
Article in En | MEDLINE | ID: mdl-34657218
ABSTRACT
This study describes the acceptability of a rectal microbicide gel formulation using dapivirine (DPV) among men and women from two countries (United States and Thailand) participating in the Microbicide Trials Network-026 trial. We evaluated participants' acceptability of a rectal DPV/placebo gel as part of a Phase I trial (N = 26; 18 male, 8 female). Participants reported favorable acceptability of the study gel, with most participants reporting that they liked the gel the same (n = 14; 53.8%) or more (n = 11; 42.4%) than when they started the trial. Over half of participants noted that they would prefer the gel over condoms (n = 13; 50%) or that they liked condoms and the gel equally (n = 8; 30.8%). Side effects across products included leakage (n = 8; 30.8%), diarrhea (n = 4; 15.4%), or soiling (n = 1; 3.8%). The high acceptability of a rectal gel underscores its promise as a short-acting biomedical prevention, warranting future research for HIV prevention.Trial Registration NCT03239483.
RESUMEN
RESUMEN Este estudio describe la aceptabilidad de un microbicida rectal (RM) con dapivirina (DPV) formulado como un gel por hombres y mujeres de dos países (Estados Unidos y Tailandia) que participaron como parte del Microbicide Trials Network (MTN)-026. Evaluamos la aceptabilidad de un gel rectal de DPV y un placebo como parte de un estudio de Fase I (N = 26; 18 hombres, 8 mujeres). Los participants informaron una aceptabilidad favorable sobre el gel del estudio; la mayoría de los participantes informaron que les gustó el gel igual (n = 14; 53.8%) o más (n = 11; 42.4%) que cuando comenzaron el estudio. Más de la mitad de los participantes señalaron que preferirían el gel sobre los condones (n = 13; 50%) o que les gustaban los condones y el gel por igual (n = 8; 30,8%). Los efectos de los productos incluyeron fugas (n = 8; 30,8%), diarrea (n = 4; 15,4%) o ensuciamiento (n = 1; 3,8%). La alta aceptabilidad de un gel rectal enfatiza su promesa para la prevención biomédica de acción corta y justifica futuras investigaciones para la prevención del VIH.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / HIV-1 / Anti-Infective Agents Type of study: Clinical_trials Limits: Adult / Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: AIDS Behav Journal subject: CIENCIAS DO COMPORTAMENTO / SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2022 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / HIV-1 / Anti-Infective Agents Type of study: Clinical_trials Limits: Adult / Female / Humans / Male Country/Region as subject: America do norte Language: En Journal: AIDS Behav Journal subject: CIENCIAS DO COMPORTAMENTO / SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 2022 Document type: Article Affiliation country: United States
...